DK3363438T3 - Substituerede 2-azabicykler og deres anvendelse som orexinreceptormodulatorer - Google Patents

Substituerede 2-azabicykler og deres anvendelse som orexinreceptormodulatorer Download PDF

Info

Publication number
DK3363438T3
DK3363438T3 DK17206491T DK17206491T DK3363438T3 DK 3363438 T3 DK3363438 T3 DK 3363438T3 DK 17206491 T DK17206491 T DK 17206491T DK 17206491 T DK17206491 T DK 17206491T DK 3363438 T3 DK3363438 T3 DK 3363438T3
Authority
DK
Denmark
Prior art keywords
azabic
cycles
substituted
receptor modulators
orexin receptor
Prior art date
Application number
DK17206491T
Other languages
Danish (da)
English (en)
Inventor
Christine F Gelin
Terry P Lebold
Brock T Shireman
Jeannie M Ziff
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK3363438T3 publication Critical patent/DK3363438T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK17206491T 2013-03-13 2014-03-12 Substituerede 2-azabicykler og deres anvendelse som orexinreceptormodulatorer DK3363438T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780378P 2013-03-13 2013-03-13
EP14717576.4A EP2970314B1 (en) 2013-03-13 2014-03-12 Substituted 2-azabicycles and their use as orexin receptor modulators

Publications (1)

Publication Number Publication Date
DK3363438T3 true DK3363438T3 (da) 2019-11-11

Family

ID=50487148

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14717576.4T DK2970314T3 (en) 2013-03-13 2014-03-12 SUBSTITUTED 2-AZABIC CYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS
DK17206491T DK3363438T3 (da) 2013-03-13 2014-03-12 Substituerede 2-azabicykler og deres anvendelse som orexinreceptormodulatorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14717576.4T DK2970314T3 (en) 2013-03-13 2014-03-12 SUBSTITUTED 2-AZABIC CYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

Country Status (38)

Country Link
US (5) US9611277B2 (enExample)
EP (4) EP4272824A3 (enExample)
JP (1) JP6275815B2 (enExample)
KR (1) KR102209424B1 (enExample)
CN (3) CN108864093A (enExample)
AR (1) AR095423A1 (enExample)
AU (2) AU2014248680B2 (enExample)
BR (1) BR112015022294B1 (enExample)
CA (1) CA2904618C (enExample)
CL (1) CL2015002609A1 (enExample)
CR (2) CR20210523A (enExample)
CY (3) CY1120024T1 (enExample)
DK (2) DK2970314T3 (enExample)
EA (1) EA029276B1 (enExample)
ES (3) ES2659397T3 (enExample)
HR (3) HRP20230633T1 (enExample)
HU (3) HUE063608T2 (enExample)
IL (2) IL240466B (enExample)
JO (1) JOP20140092B1 (enExample)
LT (2) LT2970314T (enExample)
ME (2) ME03572B (enExample)
MX (2) MX368466B (enExample)
MY (1) MY183725A (enExample)
NI (1) NI201500130A (enExample)
NO (1) NO3107630T3 (enExample)
PE (1) PE20151599A1 (enExample)
PH (1) PH12015501929A1 (enExample)
PL (3) PL2970314T3 (enExample)
PT (2) PT3363438T (enExample)
RS (3) RS59466B1 (enExample)
SG (1) SG11201507415QA (enExample)
SI (2) SI3363438T1 (enExample)
SM (3) SMT202300223T1 (enExample)
TW (1) TWI621618B (enExample)
UA (1) UA118669C2 (enExample)
UY (1) UY35409A (enExample)
WO (1) WO2014165070A1 (enExample)
ZA (1) ZA201507562B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2491038B1 (en) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
PE20170184A1 (es) 2014-03-06 2017-04-07 Shanghai Haiyan Pharmaceutical Tech Co Ltd Derivados de piperidina como antagonista de receptores de orexina
MX2017003254A (es) * 2014-09-11 2017-10-12 Janssen Pharmaceutica Nv 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
WO2016100157A2 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
CN111848603B (zh) * 2015-08-14 2022-08-09 上海海雁医药科技有限公司 食欲素受体拮抗剂受体化合物的制备方法及其中间体和晶型
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CA3005918C (en) 2015-11-23 2023-10-17 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
US10828302B2 (en) 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
US11306070B2 (en) 2016-11-22 2022-04-19 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
US11660293B2 (en) * 2017-09-01 2023-05-30 Chronos Therapeutics Limited Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
CN112367991A (zh) 2018-06-25 2021-02-12 达纳-法伯癌症研究所股份有限公司 Taire家族激酶抑制剂及其用途
CN113164477A (zh) * 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
CN118388474A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674793A (en) 1967-03-29 1972-07-04 Sterling Drug Inc 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones
US6505492B2 (en) 2001-04-11 2003-01-14 Bethlehem Steel Corporation Method and apparatus for forming deep-drawn articles
WO2002094790A1 (en) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
EP1594852A1 (en) 2003-02-07 2005-11-16 Ranbaxy Laboratories, Ltd. Oxazolidinone derivatives as antimicrobials
EP1599483A1 (en) 2003-02-21 2005-11-30 Pharmacia & Upjohn Company LLC Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo 2.2.1 heptane- 7-carboxylate, intermediates, and process to prepare and isolate them
JP2009519986A (ja) 2005-12-20 2009-05-21 ノバルティス アクチエンゲゼルシャフト 代謝型グルタミン酸受容体のモジュレーターとしてのニコチン酸誘導体
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
CA2669060A1 (en) 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd Piperidine compounds
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
CA2687230A1 (en) * 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
NZ582661A (en) 2007-07-17 2012-03-30 Bristol Myers Squibb Co Method for modulating gpr119 g protein-coupled receptor and selected compounds
CN101903372B (zh) 2007-12-21 2014-06-18 弗·哈夫曼-拉罗切有限公司 作为食欲肽受体拮抗剂的杂芳基衍生物
EP2247586B1 (en) * 2008-02-21 2012-04-25 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
CN102015645B (zh) 2008-04-30 2012-11-14 埃科特莱茵药品有限公司 哌啶和吡咯烷化合物
MX2011000664A (es) 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
EP2349269A4 (en) 2008-10-21 2012-04-25 Merck Sharp & Dohme 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
AU2009307920A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
MX2011005800A (es) 2008-12-02 2011-06-20 Glaxo Group Ltd Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos.
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
EA201171293A1 (ru) 2009-04-24 2012-05-30 Глэксо Груп Лимитед 3-азабицикло[4.1.0]гептаны, применяемые в качестве антагонистов орексина
US9062044B2 (en) 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
EP2491034B1 (en) 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
EP2491038B1 (en) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
US9409918B2 (en) 2009-10-29 2016-08-09 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
EP2503887B1 (en) 2009-11-24 2016-01-06 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
JP2013513664A (ja) 2009-12-14 2013-04-22 インスパイアー ファーマシューティカルズ，インコーポレイティド 架橋二環式ｒｈｏキナーゼ阻害化合物、組成および使用
WO2011087812A1 (en) 2009-12-21 2011-07-21 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011159657A1 (en) 2010-06-18 2011-12-22 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9546152B2 (en) 2012-10-23 2017-01-17 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
AU2013347538B2 (en) 2012-11-16 2017-04-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
KR20160118345A (ko) 2014-02-06 2016-10-11 애브비 인코포레이티드 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도
MX2017003254A (es) 2014-09-11 2017-10-12 Janssen Pharmaceutica Nv 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.

Also Published As

Publication number Publication date
PT2970314T (pt) 2018-03-05
HRP20192032T1 (hr) 2020-02-07
US9447117B2 (en) 2016-09-20
HRP20180303T1 (hr) 2018-03-23
CR20210523A (es) 2021-11-19
EP3622956C0 (en) 2023-06-07
SG11201507415QA (en) 2015-10-29
US10183953B2 (en) 2019-01-22
AU2014248680B2 (en) 2018-07-26
EP3622956B9 (en) 2023-09-27
SMT201800056T1 (it) 2018-03-08
CY1126106T1 (el) 2023-11-15
ME03572B (me) 2020-07-20
KR102209424B1 (ko) 2021-01-29
EP3363438A1 (en) 2018-08-22
LT3363438T (lt) 2019-11-11
CR20150433A (es) 2015-10-26
ES2760564T3 (es) 2020-05-14
AU2014248680A1 (en) 2015-08-27
PL2970314T3 (pl) 2018-05-30
PL3363438T3 (pl) 2020-02-28
EP4272824A3 (en) 2024-01-10
EA029276B1 (ru) 2018-03-30
US20170204096A1 (en) 2017-07-20
CY1120024T1 (el) 2018-12-12
CL2015002609A1 (es) 2016-03-28
NZ710872A (en) 2020-10-30
US9611277B2 (en) 2017-04-04
RS64551B1 (sr) 2023-10-31
AU2018204835B2 (en) 2019-08-08
SI2970314T1 (en) 2018-02-28
MY183725A (en) 2021-03-10
EP3363438B1 (en) 2019-09-18
PH12015501929B1 (en) 2016-01-04
CN105308048A (zh) 2016-02-03
AR095423A1 (es) 2015-10-14
HUE047592T2 (hu) 2020-05-28
US20160052939A1 (en) 2016-02-25
EP3622956A1 (en) 2020-03-18
HRP20230633T1 (hr) 2023-09-29
CN110669052B (zh) 2022-10-11
PL3622956T3 (pl) 2023-09-18
JOP20140092B1 (ar) 2021-08-17
JP6275815B2 (ja) 2018-02-07
US20140275118A1 (en) 2014-09-18
SI3363438T1 (sl) 2019-11-29
CA2904618A1 (en) 2014-10-09
CN105308048B (zh) 2019-10-08
IL240466B (en) 2019-03-31
CA2904618C (en) 2021-12-07
EP2970314B1 (en) 2017-12-13
RS59466B1 (sr) 2019-11-29
PH12015501929A1 (en) 2016-01-04
BR112015022294B1 (pt) 2022-09-13
NI201500130A (es) 2015-11-30
CY1122392T1 (el) 2021-01-27
MX361529B (es) 2018-12-07
HK1219725A1 (en) 2017-04-13
WO2014165070A1 (en) 2014-10-09
CN110669052A (zh) 2020-01-10
EP4272824A2 (en) 2023-11-08
ES2950032T3 (es) 2023-10-04
PT3363438T (pt) 2019-12-11
US8969352B2 (en) 2015-03-03
DK2970314T3 (en) 2018-02-26
HUE063608T2 (hu) 2024-01-28
BR112015022294A2 (pt) 2017-07-18
ME03011B (me) 2018-10-20
ZA201507562B (en) 2019-04-24
UY35409A (es) 2014-09-30
RS56875B1 (sr) 2018-04-30
KR20150126694A (ko) 2015-11-12
EP3622956B1 (en) 2023-06-07
US20150174129A1 (en) 2015-06-25
ES2659397T3 (es) 2018-03-15
EA201591703A1 (ru) 2016-02-29
EP2970314A1 (en) 2016-01-20
UA118669C2 (uk) 2019-02-25
PE20151599A1 (es) 2015-11-12
RS64551B9 (sr) 2023-12-29
TWI621618B (zh) 2018-04-21
MX2015011815A (es) 2016-11-07
MX368466B (es) 2019-10-03
CN108864093A (zh) 2018-11-23
SMT202300223T1 (it) 2023-09-06
HUE036193T2 (hu) 2018-06-28
US9845333B2 (en) 2017-12-19
IL240466A0 (en) 2015-09-24
US20170015651A1 (en) 2017-01-19
AU2018204835A1 (en) 2018-07-19
NO3107630T3 (enExample) 2018-01-06
IL264606A (en) 2019-02-28
JP2016512535A (ja) 2016-04-28
LT2970314T (lt) 2018-02-12
TW201446757A (zh) 2014-12-16
SMT201900655T1 (it) 2020-01-14

Similar Documents

Publication Publication Date Title
DK3363438T3 (da) Substituerede 2-azabicykler og deres anvendelse som orexinreceptormodulatorer
DK3848027T3 (da) Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer
DK2951183T3 (da) Spiro-lactam-nmda-receptormodulatorer og anvendelser heraf
DK3039148T3 (da) Transduktionsbuffer
IL240929B (en) 7- Converted azabicycles and their use as orexin receptor modulators
HRP20182004T1 (hr) Tetrahidropiridopirazini modulatori gpr6
ES2635318T7 (es) Moduladores P2X7
DK3385545T3 (da) Forbindelsesorgan
DK2970442T3 (da) Gla-domæner som terapeutiske midler
DK2964623T3 (da) Substituerede chroman-6-yloxycycloalkaner og deres anvendelse som farmaceutik
BR302012005816S1 (pt) Configuração aplicada em gabinete
BR302013006067S1 (pt) Configuração aplicada em espumadeira
BR302013004005S1 (pt) Configuração aplicada em brinquedo
BR302013003082S1 (pt) Configuração aplicada em brinquedo
BR302013005981S1 (pt) Configuração aplicada em urso de brinquedo
BR302013004792S1 (pt) Configuração aplicada em óculos de brinquedo
BR302013004403S1 (pt) Configuração aplicada em balança
BR302013005366S1 (pt) Configuração aplicada em viola
BR302013003017S1 (pt) Configuração aplicada em cabide com gancho
BR302012002681S1 (pt) Configuração aplicada em gabinete
BR302013005228S1 (pt) Configuração aplicada em poltrona
BR302013002859S1 (pt) Configuração aplicada em poltrona
BR302013002721S1 (pt) Configuração aplicada em poltrona